CMS: Rxilient Obtained Commercialization Rights for Dermatology Improved New Drug Finjuve and Branded Drug Ciclopoli in Southeast Asia and Other Markets

Finjuve, animproved new drug, is the first and only topical finasteride product worldwide approved for the treatment of androgenetic alopecia. Its efficacy is comparable to oral finasteride, while showing 100-fold lower systemic exposure and less impact on serum DHT levels compared with oral finasteride, offering an effective hair-loss treatment option with lower risk. Ciclopoli, a branded drug, uses patented HPCH water-soluble transungual technology. It does not require nail filing or organic solvents to remove the film, combining strong efficacy, safety, and convenience, and offering a superior topical treatment option for onychomycosis patients. Leveraging itsestablished registration and commercialization capabilities across Southeast Asia, Rxilient will accelerate the launch of both products, injecting new momentum into business growth in the region.   Recently, the Southeast Asia business subsidiary of China Medical System (“CMS”), Rxilient Medical Pte. Ltd. (“Rxilient”), entered into a partnership with Polichem S.A., a subsidiary of Almirall S.A. (ALM), a global biopharmaceutical company focused on medical dermatology. Rxilient obtained […]